论文部分内容阅读
目的:观察熄风涤痰汤联合左乙拉西坦片治疗癫痫急性期风痰闭阻证患者的效果。方法:将136例癫痫急性期风痰闭阻证患者随机分为对照组和观察组各68例。对照组给予左乙拉西坦片内服,观察组加用自拟熄风涤痰汤内服治疗,2组均连续用药6月。比较2组的临床疗效,记录患者治疗前后每月的癫痫发作频数,治疗前后用蒙特利尔认知评估量表(Mo CA)对认知功能进行评价。结果:观察组总有效率为85.3%,与对照组的69.1%相比,差异有统计学意义(P<0.05)。治疗前,2组癫痫发作频数、Mo CA评分比较,差异均无统计学意义(P>0.05)。治疗后,2组的癫痫发作频数均较治疗前减少,Mo CA评分较治疗前提高,差异均有统计学意义(P<0.05);观察组每月癫痫发作频数少于对照组,Mo CA评分高于对照组,差异均有统计学意义(P<0.05)。结论:熄风涤痰汤联合左乙拉西坦片治疗癫痫急性期风痰闭阻证患者疗效确切,能显著提高患者的认知功能。
Objective: To observe the effect of Xifengditan combined with levetiracetam on patients with wind-phlegm obstruction in the acute stage of epilepsy. Methods: A total of 136 patients with epilepsy phlegm obstruction in the acute stage were randomly divided into control group and observation group, 68 cases each. The control group was given levetiracetam orally, and the observation group was treated with orally administered Xifengditang decoction orally. Both groups were given continuous treatment for 6 months. The clinical efficacy of the two groups were compared. The frequency of seizures was recorded before and after treatment. The cognitive function was evaluated by the Montreal Cognitive Assessment Scale (MoCA) before and after treatment. Results: The total effective rate in the observation group was 85.3%, which was significantly different from that in the control group (69.1%) (P <0.05). Before treatment, there were no significant differences in seizure frequency and MoCA scores between the two groups (P> 0.05). After treatment, the frequency of seizures in both groups decreased compared with that before treatment, and the MoCA score was significantly higher than that before treatment (P <0.05). The monthly seizure frequency in the observation group was less than that in the control group. MoCA score Higher than the control group, the difference was statistically significant (P <0.05). Conclusion: Xifengditan Decoction combined with levetiracetam tablets in the treatment of patients with acute phlebitis obstruction of epilepsy is effective and can significantly improve the cognitive function of patients.